Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 86

1.

The effects of HCV infection and management on health-related quality of life.

Younossi Z, Kallman J, Kincaid J.

Hepatology. 2007 Mar;45(3):806-16. Review.

PMID:
17326207
[PubMed - indexed for MEDLINE]
2.

Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.

Manns MP, Markova AA, Calle Serrano B, Cornberg M.

Liver Int. 2012 Feb;32 Suppl 1:27-31. doi: 10.1111/j.1478-3231.2011.02725.x. Review.

PMID:
22212568
[PubMed - indexed for MEDLINE]
3.

Treatment of chronic hepatitis C in southern Taiwan.

Chuang WL, Yu ML, Dai CY, Chang WY.

Intervirology. 2006;49(1-2):99-106. Review.

PMID:
16166797
[PubMed - indexed for MEDLINE]
4.

Efficacy of peginterferon alpha-2A and ribavirin combination therapy in treatment-naive Estonian patients with chronic hepatitis C.

Brjalin V, Salupere R, Tallo T, Kuznetsova T, Priimägi L, Tefanova V.

Cent Eur J Public Health. 2012 Jun;20(2):150-5.

PMID:
22966742
[PubMed - indexed for MEDLINE]
5.

Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.

Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study [KULDS] Group.

J Gastroenterol Hepatol. 2012 Jul;27(7):1233-40. doi: 10.1111/j.1440-1746.2011.06965.x.

PMID:
22098185
[PubMed - indexed for MEDLINE]
6.

Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.

Hung CH, Lu SN, Wang JH, Hu TH, Chen CH, Huang CM, Lee CM.

Antivir Ther. 2011;16(7):959-68. doi: 10.3851/IMP1842.

PMID:
22024511
[PubMed - indexed for MEDLINE]
7.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

PMID:
15461877
[PubMed - indexed for MEDLINE]
Free Article
8.

Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.

Labarga P, Barreiro P, da Silva A, Guardiola JM, Rubio R, Aguirrebengoa K, Miralles P, Portu J, Téllez MJ, Morano L, Castro A, Pineda JA, Terrón A, Hernández-Quero J, Mariño A, Ríos MJ, Echeverría S, Asensi V, Vispo E, Soriano V; PERICO Study Group.

J Infect Dis. 2012 Sep 15;206(6):961-8. Epub 2012 Jul 17.

PMID:
22807523
[PubMed - indexed for MEDLINE]
Free Article
9.
10.

Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks.

Sarrazin C, Schwendy S, Möller B, Dikopoulos N, Buggisch P, Encke J, Teuber G, Goeser T, Thimme R, Klinker H, Boecher WO, Schulte-Frohlinde E, Prinzing R, Herrmann E, Zeuzem S, Berg T.

Gastroenterology. 2011 Nov;141(5):1656-64. doi: 10.1053/j.gastro.2011.07.019. Epub 2011 Jul 22.

PMID:
21784046
[PubMed - indexed for MEDLINE]
11.

Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.

Hartwell D, Jones J, Baxter L, Shepherd J.

Health Technol Assess. 2011 Apr;15(17):i-xii, 1-210. doi: 10.3310/hta15170. Review.

PMID:
21473834
[PubMed - indexed for MEDLINE]
Free Article
12.

A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C.

Thu Thuy PT, Bunchorntavakul C, Tan Dat H, Rajender Reddy K.

J Hepatol. 2012 May;56(5):1012-8. doi: 10.1016/j.jhep.2011.12.020. Epub 2012 Jan 17.

PMID:
22266603
[PubMed - indexed for MEDLINE]
13.

Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.

Alsaran K, Sabry A, Shaheen N.

Int Urol Nephrol. 2011 Sep;43(3):865-73. doi: 10.1007/s11255-010-9756-1. Epub 2010 May 19.

PMID:
20490669
[PubMed - indexed for MEDLINE]
14.

Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.

Napoli N, Giannelli G, Parisi CV, Antonaci A, Maddalena G, Antonaci S.

New Microbiol. 2005 Jan;28(1):13-21.

PMID:
15782622
[PubMed - indexed for MEDLINE]
15.

Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.

Schaefer M, Hinzpeter A, Mohmand A, Janssen G, Pich M, Schwaiger M, Sarkar R, Friebe A, Heinz A, Kluschke M, Ziemer M, Gutsche J, Weich V, Halangk J, Berg T.

Hepatology. 2007 Oct;46(4):991-8.

PMID:
17668880
[PubMed - indexed for MEDLINE]
16.

Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies.

Soriano V, Maida I, Núñez M, García-Samaniego J, Barreiro P, Martín-Carbonero L, González-Lahoz J.

Antivir Ther. 2004 Dec;9(6):987-92.

PMID:
15651757
[PubMed - indexed for MEDLINE]
17.

Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.

Kurosaki M, Tanaka Y, Tanaka K, Suzuki Y, Hoshioka Y, Tamaki N, Kato T, Yasui Y, Hosokawa T, Ueda K, Tsuchiya K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Matsuura K, Sugauchi F, Enomoto N, Nishida N, Tokunaga K, Mizokami M, Izumi N.

Antivir Ther. 2011;16(5):685-94. doi: 10.3851/IMP1796.

PMID:
21817190
[PubMed - indexed for MEDLINE]
18.

Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.

Angelico M, Koehler-Horst B, Piccolo P, Angelico F, Gentile S, Francioso S, Tarquini P, Vecchia RD, Ponti L, Pilleri G, Barlattani A, Grieco A, Soccorsi F, Guarascio P, Demelia L, Sorbello O, Rossi Z, Forlini G, Zaru S, Bandiera F; SMIEC II Investigators.

Eur J Gastroenterol Hepatol. 2008 Jul;20(7):680-7. doi: 10.1097/MEG.0b013e3282f5196c.

PMID:
18679072
[PubMed - indexed for MEDLINE]
19.

Chronic hepatitis C treatment in näive patients.

Daruich J.

Ann Hepatol. 2010;9 Suppl:65-71.

PMID:
20713999
[PubMed - indexed for MEDLINE]
20.

[Efficacy and safety of peginterferon alfa-2a and ribavirin treatment of chronic hepatitis C in the Republic of Serbia].

Božić M, Bojović K, Fabri M, Nožić D, Trkulja B, Milošević I.

Srp Arh Celok Lek. 2012 Jul-Aug;140(7-8):448-55. Serbian.

PMID:
23092029
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk